Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Maartje Van Ruiten, Nienke E. van Trommel, Ekaterina S. Jordanova, John B. A. G. Haanen, Ton N. Schumacher, Gemma G. Kenter, Jossie Rotman, Marc van Beurden, Noor A. M. Bakker, Sanne Samuels, Bastiaan Nuijen, Karin E. de Visser, Tanja D. de Gruijl, Jos H. Beijnen, Henry Zijlmans, Joost H. van den Berg
Publikováno v:
Bakker, N A M, Rotman, J, Van Beurden, M, Zijlmans, H J M A A, Van Ruiten, M, Samuels, S, Nuijen, B, Beijnen, J, De Visser, K, Haanen, J, Schumacher, T, De Gruijl, T D, Jordanova, E S, Kenter, G G, Van Den Berg, J H & Van Trommel, N E 2021, ' HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN) : A phase I/II clinical trial ', Journal for Immunotherapy of Cancer, vol. 9, no. 8, 002547 . https://doi.org/10.1136/jitc-2021-002547
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
BackgroundUsual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical excis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb52bf3c6adfbc91bc3923e54b6cf18
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
Autor:
Ada M. Kruisbeek, Tanja D. de Gruijl, Malika Koppes, Jorn Kaspers, Sandra van Wetering, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Saskia J. A. M. Santegoets, Yvonne den Hartog, Corien Eeltink, Satwinder Kaur Singh
Publikováno v:
Cancer Immunology, Immunotherapy
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518
In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel allogeneic
Autor:
Alfons J.M. van den Eertwegh, Natalie Sacks, Rik J. Scheper, Israel Lowy, Jean Marie Cuillerot, Petra E.T. Scholten, Helen Gall, Martine Reijm, Karin Jooss, Winald R. Gerritsen, Sinéad M. Lougheed, B. Mary E. von Blomberg, Anita G.M. Stam, Tanja D. de Gruijl, Saskia J. A. M. Santegoets, Kristen Hege
Publikováno v:
Cancer Immunology Immunotherapy, 62, 245-56
Cancer Immunology and Immunotherapy, 62(2), 245-256. Springer Science and Business Media Deutschland GmbH
Santegoets, S J A M, Stam, A G M, Lougheed, S M, Gall, H, Scholten, P E T, Reijm, M, Jooss, K, Sacks, N, Hege, K, Lowy, I, Cuillerot, J M, von Blomberg, B M E, Scheper, R J, van den Eertwegh, A J M, Gerritsen, W R & de Gruijl, T D 2013, ' T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment ', Cancer Immunology and Immunotherapy, vol. 62, no. 2, pp. 245-256 . https://doi.org/10.1007/s00262-012-1330-5
Cancer Immunology Immunotherapy, 62, 2, pp. 245-56
Cancer Immunology and Immunotherapy, 62(2), 245-256. Springer Science and Business Media Deutschland GmbH
Santegoets, S J A M, Stam, A G M, Lougheed, S M, Gall, H, Scholten, P E T, Reijm, M, Jooss, K, Sacks, N, Hege, K, Lowy, I, Cuillerot, J M, von Blomberg, B M E, Scheper, R J, van den Eertwegh, A J M, Gerritsen, W R & de Gruijl, T D 2013, ' T cell profiling reveals high CD4(+)CTLA-4(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment ', Cancer Immunology and Immunotherapy, vol. 62, no. 2, pp. 245-256 . https://doi.org/10.1007/s00262-012-1330-5
Cancer Immunology Immunotherapy, 62, 2, pp. 245-56
Item does not contain fulltext Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify
Autor:
Alfons J.M. van den Eertwegh, Thomas Harding, Natalie Sacks, Saskia J. A. M. Santegoets, R. Jeroen A. van Moorselaar, Kristen Hege, Rik J. Scheper, Israel Lowy, Winald R. Gerritsen, Tim M. van der Sluis, Herbert M. Pinedo, Karin Jooss, Anita G.M. Stam, Jurjen Versluis, B. Mary E. von Blomberg, H Pieter van den Berg, Tanja D. de Gruijl, H.E. Gall
Publikováno v:
van den Eertwegh, A J M, Versluis, J P, van den Berg, H P, Santegoets, S J A M, van Moorselaar, R J A, van der Sluis, T M, Gall, H E, Harding, T C, Jooss, K, Lowy, I, Pinedo, H M, Scheper, R J, Stam, A G M, von Blomberg, B M E, de Gruijl, T D, Hege, K, Sacks, N & Gerritsen, W R 2012, ' Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial ', Lancet Oncology, vol. 13, no. 5, pp. 509-517 . https://doi.org/10.1016/S1470-2045(12)70007-4
Lancet Oncology, 13, 5, pp. 509-17
Lancet Oncology, 13, 509-17
Lancet Oncology, 13(5), 509-517. Lancet Publishing Group
Lancet Oncology, 13, 5, pp. 509-17
Lancet Oncology, 13, 509-17
Lancet Oncology, 13(5), 509-517. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity against prostate cancer; preclinical studies have shown potent synergy